{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:19:07Z","timestamp":1792081147950,"version":"4.4.0"},"reference-count":61,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors have revolutionized cancer therapy but are associated with a risk of endocrine immune-related adverse events, including pituitary complications. Autoimmune hypophysitis, traditionally a rare diagnosis, has become a more frequently encountered clinical entity with the emergence of antitumor immunotherapy. This mini-review aims to consolidate current knowledge, encompassing the epidemiology, pathophysiology, clinical presentation, diagnosis, and management of pituitary complications of immune checkpoint inhibitor use.<\/jats:p>","DOI":"10.1210\/endocr\/bqae084","type":"journal-article","created":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T10:18:06Z","timestamp":1720865886000},"source":"Crossref","is-referenced-by-count":13,"title":["Pituitary Complications of Checkpoint Inhibitor Use"],"prefix":"10.1210","volume":"165","author":[{"given":"Natalia","family":"Chamorro-Pareja","sequence":"first","affiliation":[{"name":"Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School , Boston, MA 02114 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T","family":"Faje","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School , Boston, MA 02114 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9438-2449","authenticated-orcid":false,"given":"Karen K","family":"Miller","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School , Boston, MA 02114 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,7,13]]},"reference":[{"issue":"7","key":"2024082704363093600_bqae084-B1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2217\/imt-2016-0002","article-title":"Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges","volume":"8","author":"Kyi","year":"2016","journal-title":"Immunotherapy"},{"issue":"1","key":"2024082704363093600_bqae084-B2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2024082704363093600_bqae084-B3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1210\/clinem\/dgab672","article-title":"Hypophysitis, the growing spectrum of a rare pituitary disease","volume":"107","author":"Langlois","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"9-10","key":"2024082704363093600_bqae084-B4","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1159\/000506903","article-title":"Hypophysitis (Including IgG4 and immunotherapy)","volume":"110","author":"Angelousi","year":"2020","journal-title":"Neuroendocrinology"},{"issue":"3","key":"2024082704363093600_bqae084-B5","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1210\/jcem.86.3.7265","article-title":"The spectrum and significance of primary hypophysitis","volume":"86","author":"Cheung","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024082704363093600_bqae084-B6","doi-asserted-by":"crossref","first-page":"101371","DOI":"10.1016\/j.beem.2019.101371","article-title":"Hypophysitis: an update on the novel forms, diagnosis and management of disorders of pituitary inflammation","volume":"33","author":"Gubbi","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"2024082704363093600_bqae084-B7","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2024082704363093600_bqae084-B8","doi-asserted-by":"crossref","first-page":"582394","DOI":"10.3389\/fonc.2020.582394","article-title":"Case report: ipilimumab-induced panhypophysitis: an infrequent occurrence and literature review","volume":"10","author":"Barnabei","year":"2020","journal-title":"Front Oncol"},{"issue":"2","key":"2024082704363093600_bqae084-B9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1210\/jc.2017-01905","article-title":"Anti-PD-L1 treatment induced central diabetes insipidus","volume":"103","author":"Zhao","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2024082704363093600_bqae084-B10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejca.2018.09.016","article-title":"Hypothalamitis and severe hypothalamic dysfunction associated with anti-programmed cell death ligand 1 antibody treatment","volume":"104","author":"Tshuma","year":"2018","journal-title":"Eur J Cancer"},{"key":"2024082704363093600_bqae084-B11","doi-asserted-by":"crossref","first-page":"106427","DOI":"10.1016\/j.intimp.2020.106427","article-title":"Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy","volume":"83","author":"Deligiorgi","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"15","key":"2024082704363093600_bqae084-B12","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/imt-2020-0334","article-title":"Anti-PD-1 treatment-induced immediate central diabetes insipidus: a case report","volume":"13","author":"Yu","year":"2021","journal-title":"Immunotherapy"},{"issue":"1","key":"2024082704363093600_bqae084-B13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3892\/etm.2022.11709","article-title":"Diabetes insipidus: a rare endocrine complication of immune check point inhibitors: a case report and literature review","volume":"25","author":"Angelousi","year":"2023","journal-title":"Exp Ther Med"},{"issue":"3","key":"2024082704363093600_bqae084-B14","doi-asserted-by":"crossref","first-page":"e200423","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2024082704363093600_bqae084-B15","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/jim-2021-002099","article-title":"Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort","volume":"70","author":"Kotwal","year":"2022","journal-title":"J Investig Med"},{"issue":"6","key":"2024082704363093600_bqae084-B16","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3803\/EnM.2023.1785","article-title":"Incidence of endocrine-related dysfunction in patients treated with new immune checkpoint inhibitors: a meta-analysis and comprehensive review","volume":"38","author":"Yoo","year":"2023","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"11","key":"2024082704363093600_bqae084-B17","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-Induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024082704363093600_bqae084-B18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"5","key":"2024082704363093600_bqae084-B19","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"2024082704363093600_bqae084-B20","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE)","author":"US Department of Human and Health Services","year":"2024"},{"issue":"8","key":"2024082704363093600_bqae084-B21","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"21","key":"2024082704363093600_bqae084-B22","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"2024082704363093600_bqae084-B23","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2024082704363093600_bqae084-B24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"2024082704363093600_bqae084-B25","doi-asserted-by":"crossref","first-page":"e002890","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2024082704363093600_bqae084-B26","first-page":"A1309","article-title":"1263 dermatologic immune related adverse event disease definitions: a multi-institutional Delphi consensus project presented on behalf of the oncodermatology working group","volume":"10","author":"Chen","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2024082704363093600_bqae084-B27","doi-asserted-by":"crossref","first-page":"bvad019","DOI":"10.1210\/jendso\/bvad019","article-title":"Dearth of ICD codes for complications of immune checkpoint inhibitors impedes clinical care and research","volume":"7","author":"Cheung","year":"2023","journal-title":"J Endocr Soc"},{"issue":"1","key":"2024082704363093600_bqae084-B28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11060-020-03687-2","article-title":"Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database","volume":"152","author":"Mikami","year":"2021","journal-title":"J Neurooncol"},{"issue":"4","key":"2024082704363093600_bqae084-B29","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1210\/clinem\/dgad670","article-title":"Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials","volume":"109","author":"Vardarli","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024082704363093600_bqae084-B30","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2217\/fon.15.222","article-title":"Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis","volume":"12","author":"Abdel-Rahman","year":"2016","journal-title":"Future Oncol"},{"key":"2024082704363093600_bqae084-B31","doi-asserted-by":"crossref","first-page":"k793","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"issue":"3","key":"2024082704363093600_bqae084-B32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/jcph.1804","article-title":"Endocrine adverse events caused by different types and different doses of immune checkpoint inhibitors in the treatment of solid tumors: a meta-analysis and systematic review","volume":"61","author":"Yang","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"2024082704363093600_bqae084-B33","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"issue":"3","key":"2024082704363093600_bqae084-B34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"2024082704363093600_bqae084-B35","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41590-022-01289-w","article-title":"Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation","volume":"23","author":"Kennedy","year":"2022","journal-title":"Nat Immunol"},{"issue":"5","key":"2024082704363093600_bqae084-B36","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"230","key":"2024082704363093600_bqae084-B37","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"issue":"6204","key":"2024082704363093600_bqae084-B38","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science"},{"issue":"12","key":"2024082704363093600_bqae084-B39","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm.3746","article-title":"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat Med"},{"issue":"6","key":"2024082704363093600_bqae084-B40","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.jaci.2018.02.055","article-title":"Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects","volume":"142","author":"Schwab","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2024082704363093600_bqae084-B41","first-page":"41","article-title":"CTLA-4 gene polymorphism associated with Graves\u2019 disease in a Caucasian population","volume":"80","author":"Yanagawa","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024082704363093600_bqae084-B42","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1046\/j.1365-2265.1997.1710996.x","article-title":"A CTLA-4 gene polymorphism is associated with both Graves disease and autoimmune hypothyroidism","volume":"46","author":"Kotsa","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2024082704363093600_bqae084-B43","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1530\/eje.0.1500619","article-title":"The emerging role of the CTLA-4 gene in autoimmune endocrinopathies","volume":"150","author":"Vaidya","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2024082704363093600_bqae084-B44","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/hmg\/6.8.1275","article-title":"Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups","volume":"6","author":"Marron","year":"1997","journal-title":"Hum Mol Genet"},{"issue":"6939","key":"2024082704363093600_bqae084-B45","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature01621","article-title":"Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease","volume":"423","author":"Ueda","year":"2003","journal-title":"Nature"},{"issue":"12","key":"2024082704363093600_bqae084-B46","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/pin.13161","article-title":"An autopsy case study of lymphocytic hypophysitis induced by nivolumab treatment for esophageal malignant melanoma","volume":"71","author":"Okabe","year":"2021","journal-title":"Pathol Int"},{"issue":"3","key":"2024082704363093600_bqae084-B47","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"2024082704363093600_bqae084-B48","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejca.2020.02.049","article-title":"Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency","volume":"130","author":"Yano","year":"2020","journal-title":"Eur J Cancer"},{"issue":"2","key":"2024082704363093600_bqae084-B49","doi-asserted-by":"crossref","first-page":"e000779","DOI":"10.1136\/jitc-2020-000779","article-title":"Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study","volume":"8","author":"Kobayashi","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"12","key":"2024082704363093600_bqae084-B50","doi-asserted-by":"crossref","first-page":"e2246400","DOI":"10.1001\/jamanetworkopen.2022.46400","article-title":"Analysis of human leukocyte antigen DR alleles, immune-related adverse events, and survival associated with immune checkpoint inhibitor use among patients with advanced malignant melanoma","volume":"5","author":"Akturk","year":"2022","journal-title":"JAMA Network Open"},{"issue":"6","key":"2024082704363093600_bqae084-B51","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/cen.14082","article-title":"Comparative analysis of human leucocyte antigen between idiopathic and anti-PD-1 antibody induced isolated adrenocorticotropic hormone deficiency: a pilot study","volume":"91","author":"Inaba","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"2024082704363093600_bqae084-B52","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s00262-021-02955-y","article-title":"Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome","volume":"70","author":"Kanie","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"44","key":"2024082704363093600_bqae084-B53","doi-asserted-by":"crossref","first-page":"22246","DOI":"10.1073\/pnas.1908079116","article-title":"Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities","volume":"116","author":"Tahir","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2024082704363093600_bqae084-B54","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2024082704363093600_bqae084-B55","first-page":"12","volume-title":"Endotext","author":"Evanson","year":"2000"},{"issue":"9","key":"2024082704363093600_bqae084-B56","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3174\/ajnr.A1623","article-title":"Ipilimumab-induced hypophysitis: MR imaging findings","volume":"30","author":"Carpenter","year":"2009","journal-title":"AJNR Am J Neuroradiol"},{"issue":"3","key":"2024082704363093600_bqae084-B57","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3390\/jpm13030415","article-title":"Pituitary enlargement and hypopituitarism in patients treated with immune checkpoint inhibitors: two sides of the same coin?","volume":"13","author":"Chiloiro","year":"2023","journal-title":"J Pers Med"},{"issue":"6","key":"2024082704363093600_bqae084-B58","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment","volume":"14","author":"Di Dalmazi","year":"2019","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"18","key":"2024082704363093600_bqae084-B59","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"issue":"12","key":"2024082704363093600_bqae084-B60","doi-asserted-by":"crossref","first-page":"e967","DOI":"10.1093\/oncolo\/oyac220","article-title":"Recurrence of hypophysitis after immune checkpoint inhibitor rechallenge","volume":"27","author":"Park","year":"2022","journal-title":"Oncologist"},{"issue":"2","key":"2024082704363093600_bqae084-B61","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur J Endocrinol"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqae084\/58536071\/bqae084.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/165\/9\/bqae084\/58875325\/bqae084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/165\/9\/bqae084\/58875325\/bqae084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:37:24Z","timestamp":1724719044000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqae084\/7713318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,13]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,7,26]]}},"URL":"https:\/\/doi.org\/10.1210\/endocr\/bqae084","relation":{},"ISSN":["1945-7170"],"issn-type":[{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,7,13]]},"article-number":"bqae084"}}